UCB: buys US epilepsy specialist Engage Therapeutics

(CercleFinance.com) - Belgian pharmaceutical company UCB on Friday announced the acquisition of Engage Therapeutics, a New Jersey-based clinical-stage firm that specialises in epilepsy, for 125 million dollars in cash.


Engage is developing Staccato Alprazolam, an investigational drug designed to be used as a single-use epileptic seizure rescue therapy that combines a small, hand-held inhaler device with a benzodiazepine.

The product could be a potential solution for 20%-30% of epilepsy patients, UCB pointed out.

UCB said up the deal could include up to 145 million dollars in further potential milestone payments related to the development of Staccato Alprazolam.

Copyright (c) 2020 CercleFinance.com. All rights reserved.